The cardiac enigma: current conundrums in heart failure research
Michael S Kapiloff1, Craig A Emter2
1Cardiac Signal Transduction and Cellular Biology Laboratory, Interdisciplinary Stem Cell Institute, Departments of Pediatrics and Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Insights
Heart failure is rising, necessitating new treatments due to static conventional therapies. Understanding cardiac remodeling and animal-to-human translation is key for novel heart failure drug discovery.
Area of Science:
- Cardiovascular Research
- Translational Medicine
- Heart Failure Pathophysiology
Background:
- Heart failure prevalence is projected to rise by nearly 50% in 15 years, driven by an aging population, increased comorbidities, and better survival post-cardiac events.
- Current heart failure treatments have seen minimal advancement in two decades, highlighting an urgent need for innovative therapeutic strategies.
- The complex and varied nature of heart failure demands precise identification of underlying cardiac cellular mechanisms to guide new treatment development.
Purpose of the Study:
- To review current research and potential challenges in cardiac disease translational research.
- To discuss future directions and considerations for advancing the development of novel heart failure therapies.
- To emphasize the importance of understanding cardiac remodeling and animal-to-human translation for cardiovascular health improvements.
Main Methods:
- Review of recent scientific literature on cardiac disease translational research.
- Analysis of challenges and successes in translating animal model findings to human heart failure.
- Discussion of cellular mechanisms, cardiac remodeling, and their role in disease progression.
Main Results:
- Identified a critical need for novel therapeutic agents due to the static nature of conventional heart failure treatments.
- Highlighted the importance of defining specific cellular mechanisms driving heart failure symptoms.
- Emphasized the challenges and opportunities in translating preclinical findings to human applications.
Conclusions:
- Advancements in understanding cardiac remodeling and animal-to-human translation are crucial for developing new heart failure therapies.
- Addressing the heterogeneity of heart failure requires a focus on specific cellular mechanisms.
- Further translational research is essential to improve cardiovascular health and patient outcomes in heart failure.
Abstract:
The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient's symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.
More Related Videos
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:29Heart Failure II: Pathophysiology
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
01:27Heart Failure I: Introduction
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy